Malin Corporation | MLC - Operating Expenses


Malin Corporation reported EUR1.1M in Operating Expenses for its fiscal semester ending in December of 2024.





Operating Expenses Change Date
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alaunos Therapeutics USD 1.01M 175K Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Avita Medical AUD 28.02M 1.55M Dec/2025
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Eurofins Scientific SE EUR 3.2B 91.8M Jun/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
IQVIA Holdings USD 1.77B 4.45B Jun/2026
Lonza CHF 2.9B 184M Jun/2025
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 960M 817M Jun/2026
Organon & Co USD 903M 387M Mar/2026
Ovoca Bio EUR 173K 990K Dec/2025
Revvity USD 603.55M 24.8M Jun/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Viatris USD 3.54B 323.9M Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026